Analysis on the medical insurance prospects and current price of capmatinib

Capmatinib (Capmatinib), as a highly selective MET inhibitor developed by Novartis, is specially designed to treat patients with non-small cell lung cancer (NSCLC) carrying METexon 14 skipping mutations. This mutation will cause abnormal activation of the MET protein and accelerate the growth and spread of tumors. Capmatinib can precisely block the MET signaling pathway, effectively inhibit tumor cell proliferation and delay disease progression, making it a new treatment option for these patients.

Currently, capmatinib has not yet been officially launched in mainland China, and domestic patients cannot directly purchase the original drug through formal channels. Foreign original drugs are expensive, with a box often costing tens of thousands of yuan. The specific price fluctuates due to regional differences. In contrast, the price of generic drugs in Laos, India and other places is relatively affordable, about 3,000 yuan, and their efficacy is similar to that of original drugs, providing more choices for patients with limited financial conditions.

Since capmatinib has not yet been included in mainland China’s medical insurance catalog, domestic patients need to purchase it at their own expense. The high cost of treatment, especially the price of original drugs, prohibits many patients. Therefore, many patients choose to purchase drugs through overseas channels or seek generic drugs as alternatives. In the future, as capmatinib gradually enters the Chinese market, it is expected to reduce the price through medical insurance negotiations and reduce the financial burden on patients.

Before using capmatinib, patients must follow the doctor's recommendation for genetic testing to confirm the presence of METexon14 skipping mutations. Accurate diagnosis is crucial to improve the effectiveness of treatment and avoid drug abuse. At the same time, patients need to regularly monitor the efficacy and adverse reactions during treatment to ensure the safety and continuity of treatment.

As a new targeted drug, capmatinib has shown great potential in the treatment of MET related lung cancer. With the in-depth promotion and research of the drug, its scope of application is expected to expand to other tumor types. At the same time, the widespread application and market competition of generic drugs may further reduce the cost of treatment, allowing more patients to benefit. In the future, the medical insurance prospects of capmatinib are worth looking forward to.

xa0

Reference materials

Novartis official website:https://www.novartis.com